Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in First-line Treatment of Poor-risk Advanced Renal Cell Carcinoma
NCT01521715Phase 4Completed
- Sponsor
- iOMEDICO
- Start
- Jan 2012
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by iOMEDICO. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Jan 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01521715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521715.